Hodgkin Lymphoma
The latest news, research, and perspectives in Hodgkin lymphoma. Both types of Hodgkin lymphoma, classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma, affect the lymphatic system and advances in diagnosis and treatment have led to high cure rates.
Advertisement
Graham Collins, MD, discusses how to navigate the latest research in Hodgkin lymphoma.
Post-AHSCT consolidation with brentuximab vedotin plus nivolumab was “highly active” in relapsed/refractory Hodgkin ...
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse.
The FDA approved brentuximab vedotin for pediatric patients with previously untreated high-risk classic Hodgkin lymphoma.
Penpulimab demonstrated a good safety profile in patients with relapsed/refractory classical Hodgkin lymphoma.
Advertisement
Long-term lymphoma survivors who underwent transplant had impaired health-related quality of life.
The allogeneic dual CAR T-cell product demonstrated preclinical activity for patients with relapsed or refractory non-Hodgkin ...
NK Cells Complexed with Bispecific Antibody Active in Advanced Lymphoma
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion ...
Oxford Biodynamics has announced the US launch of its clinical blood test predicting the likelihood of response to immune ...
Researchers examined survival rates by age in patients with Hodgkin lymphoma receiving response-adapted therapy on ...
The FDA has issued draft guidance on clinical pharmacology considerations for potential manufacturers of antibody drug ...
Researchers have discovered that chemotherapy and COVID-19 infection cause neuro-inflammation in similar ways.
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Dr. Maddocks reflects on her small-town upbringing and learning to love triathlons.
Patients in the trial were treated for lymphoma, leukemia, or multiple myeloma.
Older patients are at a significantly increased risk of immune-related AEs.
A study evaluated factors associated with intense end-of-life care among patients younger than 40 with blood cancer.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726